Baxter Intl Inc Stock Price, News & Analysis

Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share, payable on October 3, 2022, to shareholders on record as of September 2, 2022. This brings the indicated annual dividend rate to $1.16 per share. Baxter, a leader in medical technology, provides critical care and innovative healthcare solutions globally, with a mission to save and sustain lives. The company emphasizes its commitment to shareholder value through consistent dividend payments, though future payouts may vary based on financial conditions.

Baxter International Inc. (NYSE:BAX) will host a conference call on July 28, 2022, at 7:30 a.m. CT to discuss its second-quarter financial results. Interested participants can join the call via a pre-registration link or through Baxter's website. The call will be recorded and is copyrighted material.

Baxter has been a leader in medtech for 90 years, providing essential products and solutions across various care settings globally, impacting millions of patients and caregivers daily. For more information, visit www.baxter.com.

Baxter International Inc. (NYSE:BAX) is set to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 10:40 a.m. Pacific Time. José Almeida, the company’s CEO, will lead the presentation. The event will feature a live webcast, accessible at www.baxter.com, with replay available until June 13, 2023. Baxter continues to deliver critical healthcare solutions globally, enhancing patient care for nearly a century.

Baxter International (NYSE:BAX) hosted its 2022 Investor Conference, outlining its strategy for growth and innovation following the Dec. 2021 acquisition of Hillrom. The company aims to enhance patient care and operational efficiency, expecting constant currency sales growth of 4-5% from 2022-2025, with a projected adjusted operating margin increase of 350-400 basis points by 2025. Baxter anticipates $350 million in annual cost synergies and $200 million in revenue synergies by 2025 from the acquisition. Innovations showcased include the Sharesource platform and Voalte communication technologies.

Baxter International Inc. (NYSE:BAX) will host an investor conference on May 25, 2022, in Glenview, Ill.. The conference aims to provide insights into the company's growth strategy, innovation pipeline, and financial outlook. Starting at 8:00 a.m. CT, attendees can explore the innovation hall featuring product advancements, followed by management presentations at 8:30 a.m. CT. The event will also be available via live webcast on Baxter’s corporate website. Registered participants will be able to access the details of the event.

Baxter International (NYSE:BAX) has increased its quarterly cash dividend by approximately 3.5% to $0.29 per share, up from $0.28. The dividend is payable on July 1, 2022, to stockholders of record as of June 3, 2022, resulting in an annual dividend rate of $1.16 per share. CEO José Almeida emphasized the company's commitment to delivering shareholder value and advancing innovation, marking the seventh consecutive year of dividend growth.

Baxter International reported strong first-quarter 2022 results with revenues of $3.7 billion, a 26% increase year-over-year. U.S. GAAP earnings per share (EPS) were $0.14, while adjusted EPS rose 22% to $0.93. The company anticipates full-year sales growth of 23%-24% and adjusted EPS of $4.12-$4.20. Notably, acquisitions contributed significantly, with around $755 million from Hillrom. However, the Novum IQ infusion system faces FDA review delays, affecting outlook. An Investor Conference is scheduled for May 25, 2022.

Baxter International Inc. (NYSE:BAX) announced findings from a study on the Starling Registry presented at the Society of Critical Care Medicine Congress. The study, involving 127 critical care patients, indicates that monitoring stroke volume and cardiac output can predict mortality rates. Patients showing improved stroke volume had a mortality rate of 14.9%, compared to 35.0% for those without improvement. Baxter emphasizes the importance of non-invasive monitoring technology for personalized treatment decisions. The company plans further assessments of hemodynamic monitoring across various clinical settings.